• Skip to primary navigation
  • Skip to content
  • Skip to footer
Genelex Logo

Genelex

Pharmacogenetics Makes Precision Medicine Possible

  • Patients
    • Conditions
    • Affected Drugs
    • What is PGx?
    • Resources
    • FAQs
    • Patient Stories
  • Providers
    • Resources
    • Order Testing Supplies
  • Test Menu
  • Clinical Trials
  • About
    • Lab Accreditations
    • Genelex Team
    • News
    • Contact Us
  • Log In

The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery

Home / Data / The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery

Genelex Blog

The influence of NSAIDs on coumarin sensitivity in patients with CYP2C9 polymorphism after total hip replacement surgery

OBJECTIVE - To determine the influence of NSAIDs on the international normalized ratio (INR) in patients with cytochrome P450 (CYP)-2C9 enzyme variants starting acenocoumarol (an oral coumarin) therapy during the first 7 days after total hip replacement surgery.

METHODS
In this prospective study, an age-dependent protocol was used for the initiation of the acenocoumarol dose. Low-molecular-weight heparin was given for 5 days. The study included 100 patients undergoing total hip replacement surgery. After the inclusion of the last patient, polymerase chain reaction CYP2C9 mutation testing was performed for all patients. Drug-use evaluation of NSAIDs and other potential coumarin-drug interactions was also performed.

RESULTS
Eleven patients had an INR on 1 or more days >4.9. There were 52 patients who were using NSAIDs. Patients with a CYP2C9 mutation had a mean INR curve similar to patients without the mutation when NSAIDs were not coadministered. Within the group of patients heterozygous for a CYP2C9 mutation (n=30) only concomitant use of a NSAID resulted in an INR >4.9 (0% vs 38.9%, p<0.05).

CONCLUSION
In the group of patients with a CYP2C9 variant (*2 or *3 alleles), only concomitant use of a NSAID resulted in INRs >4.9. The cost effectiveness of CYP2C9 screening before elective surgery has yet to be determined.

Mol Diagn Ther. 2007;11(2):123-8

Authors: Beinema MJ, de Jong PH, Salden HJ, van Wijnen M, van der Meer J, Brouwers JR

Genelex Resources

Affected Conditions
Affected Drugs
Info for Providers
Frequently Asked Questions
Contact Genelex
Join Our Mailing List
ORDER A TEST

Take a Risk Assessment

Simply enter the medications you’re currently on or plan to take. Click “Get Results” to see if your regimen puts you at risk for an adverse drug reaction.

YOUR GENELEX RISK ASSESSMENT RESULTS:

Reader Interactions

Footer

CONTACT US

(800) 837-8362
info@genelex.com

3101 Western Ave.
Suite 100
Seattle, WA 98121

HELPFUL INFORMATION

What is PGx?
Test Menu
Conditions
Affected Drugs
Resources
FAQs

ABOUT GENELEX

Blog
News
Genelex Team
Lab Accreditations
Testimonials

  • Facebook
  • LinkedIn
  • RSS
  • Twitter
  • YouTube

KEEP IN TOUCH

Stay in the loop with news and updates from Genelex and be among the first to know when new tests become available.

© GENELEX 2019 ・ PRIVACY POLICY ・ REFERENCES ・ CAP LAB 4344001 ・CLIA 50D0980559 ・NYDOH PFI 8201